ReviewNature reviews. Microbiology2025
The global resistance problem and the clinical antibacterial pipeline.
Review in Nature reviews. Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Oral Cavity Antibacterial Discovery Pipeline Driven by Advanced Analytical Techniques.Molecules (Basel, Switzerland) · 2026Review
- Metabolic adaptations in antibiotic-resistantMicrobiology spectrum · 2026Article
- Saturated fatty acids enhance daptomycin activity in a Fak-dependent manner in enterococci.Microbiology (Reading, England) · 2026Article
- Bioactive Compounds from Mangrove-Associated Fungi as Leads Against ESKAPE Pathogens.Life (Basel, Switzerland) · 2026Review
- Genetic Elements Associated with the Acquired Resistome of the Gut Microbiota in a Broiler Rooster Flock in Hungary.Animals : an open access journal from MDPI · 2026Article
- A Self-Cascading Immunomodulatory Hydrogel for Remodeling Infected Diabetic Wounds.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- From lipophilicity windows to decision-grade antibacterial design: the next translational step for coumarin amphiphiles.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Tunable TriPcides suppress virulence factor secretion duringScience advances · 2026Article
- Article
- EnvZ/OmpR-driven cooperative behavior promotes cefiderocol resistance in a hanging-droplet evolution system.Science advances · 2026Article
- Activation of L-histidine biosynthesis as a new antibiotic strategy against Mycobacterium tuberculosis.Nature communications · 2026Article
- Bacterial cell envelope-targeting antibiotics.Nature reviews. Microbiology · 2026Review
- Molecular mechanism of action of small molecule SMT-738 on bacterial lipoprotein transporter LolCDE.Nature communications · 2026Article
- [New antimicrobial substances to combat increasing resistance].Innere Medizin (Heidelberg, Germany) · 2026Review
- Harnessing Bacterial Lipid Coatings on Gold Nanoparticles for Enhanced Cell Adhesion Applications.Small science · 2026Article
- A comparative study of intravenous polymyxin B and colistimethate sodium on efficacy, safety, and cost comparison in treating pulmonary infections: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Characterization of phage AbpL with a terminally redundant genome and its therapeutic potential against drug-resistantFrontiers in cellular and infection microbiology · 2026Article
- Next-generation anti-infective drugs in the post-antibiotic era: focusing on anti-virulence agents targeting the bacterial quorum sensing system.Frontiers in cellular and infection microbiology · 2026Review
- Cross-species transmission ofFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A comprehensive analysis of the clinical antibacterial pipeline demonstrates that there is a limited range of strategies that are primarily focused on modified versions of widely used chemical classes. These modifications aim to circumvent class-specific resistance mechanisms and reduce resistance rates in certain multidrug-resistant pathogens. Owing to the great variation in resistance rates and mechanisms, the clinical success of current approaches varies substantially across different countries, regions, and economic and environmental conditions, which affects the global societal value of these antibiotics that remain vulnerable to cross-resistance. Although there has been some progress in developing urgently needed antibiotics with novel targets and chemical structures, some of which have advanced to phase I/II trials, further breakthroughs are required. Additionally, adjunctive agents designed to enhance the outcome of conventional antibiotic therapies, along with bacteriophages that offer targeted and personalized treatments, are also under investigation. However, the potential of adjunctive therapeutics, such as antivirulence agents, and bacteriophages has yet to be realized in terms of feasibility and global societal impact.
Indexed as
Identifiers
40210708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.